Skip to content
Bored Studies
RecruitingAccepts healthy volunteersPhase 3

Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone

St. Louis University · with Orthopedic Research and Education Foundation, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · NCT03295981

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Phase 3
Target enrollment
120
US sites recruiting
11
Study start
May 3, 2018
Record last updated
April 22, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.

Being studied: Zoledronic Acid

Conditions: Giant Cell Tumor of Bone

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Primary benign GCT of bone
  • Lesion located in an extremity
  • Lesion amenable to reconstruction (intralesional curettage) defined as having at least one intact column of bone after removal
  • No previous systemic bisphosphonate or denosumab therapy

Exclusion Criteria

  • Recurrent GCT of bone
  • Non-extremity location
  • Lesion too extensive for intralesional treatment, either due to bone loss, joint invasion, or large soft tissue component
  • Children and pregnancy
  • Previous systemic bisphosphonate or denosumab therapy

Recruiting US locations

  • University of California - Los Angeles

    Los Angeles, CA 90404

    Site contact: Alexander Christ

  • Indiana University

    Indianapolis, IN 46202

    Site contact: Charalampos Lyssikatos · clyssika@iu.edu

  • University of Iowa

    Iowa City, IA 52242

    Site contact: Abigail Grothe · abigail-grothe@uiowa.edu

  • Johns Hopkins University Hospital

    Baltimore, MD 21287

    Site contact: Vaishali Laljani · vparikh2@jhmi.edu

  • Massachusetts General Hospital

    Boston, MA 02114

    Site contact: Emily Berner · EABERNER@mgh.harvard.edu

  • Boston Children's Hospital

    Boston, MA 02115

    Site contact: Saurav Pandey · Saurav.Pandey@childrens.harvard.edu

  • Beth Israel Deaconess Medical Center

    Boston, MA 02215

    Site contact: Katiri Wagner · kwagner@bidmc.harvard.edu

  • Saint Louis University

    St Louis, MO 63110

    Site contact: David Greenberg, MD · 314-617-3410 · david.greenberg@slucare.ssmhealth.com

  • Cleveland Clinic

    Cleveland, OH 44195

    Site contact: Heather Keaney, MPH · keaneyh@ccf.org

  • University of Oklahoma

    Oklahoma City, OK 73104

    Site contact: Kathy Edge · Kathy-edge@ouhsc.edu

  • Allegheny-Singer Research Institute

    Pittsburgh, PA 15212

    Site contact: Myles Forsyth · myles.forsyth@ahn.org

Study contacts (from the official record)

  • Allison Gruender, RN · 314-617-3406 · allison.gruender@health.slu.edu
  • Marsha Steffen, RN · 314-617-3410 · marsha.steffen@slucare.ssmhealth.com
All healthy volunteers studies in California →
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant… (NCT03295981) | Bored Studies